Legend Biotech Corporation (LEGN) 株式分析

企業概要

Legend Biotech Corporation operates primarily as a biopharmaceutical entity dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies targeting oncology and various other indications across the United States, China, and Europe. The company functions within the Healthcare sector and specifically the Biotechnology industry, positioning itself to capitalize on advancements in cellular medicine for serious diseases. As of the latest available data, Legend Biotech holds a market capitalization of $3.37B and generated $1.03B in annual revenue, while employing a workforce of 2,900 individuals. These valuation and revenue metrics indicate that the company has secured significant market interest and achieved substantial commercial scale, suggesting it is a major player capable of funding extensive R&D pipelines without immediate reliance on external financing.

財務健全性

The company reported a trailing twelve-month revenue of $1.03B, accompanied by a net income of $-296,800,000 and an EBITDA of $-127,100,000, revealing a substantial gap between top-line sales and bottom-line profitability. This disparity highlights a cost structure where significant operational expenses, likely driven by clinical trial costs and manufacturing overhead, consume a large portion of revenue before reaching net income. Legend Biotech maintains a cash position of $948.60M against a total debt load of $413.70M, indicating a robust liquidity buffer that supports ongoing research and development activities. However, the free cash flow stands at $-133,987,504, which implies the company is currently burning cash to fuel growth rather than generating surplus liquidity for immediate shareholder returns. The gross margin is recorded at 20.0%, while the operating margin is negative at -6.7% and the profit margin is significantly depressed at -28.8%, reflecting the typical early-stage dynamics of biotechnology firms where high R&D and commercialization costs suppress profitability metrics. Balance sheet analysis shows a debt-to-equity ratio of 41.28 and a current ratio of 1.96, suggesting a relatively conservative liquidity posture given the high current assets relative to current liabilities. Furthermore, the return on equity is -29.1% and the return on assets is -5.0%, metrics that reveal management is currently prioritizing long-term asset accumulation and pipeline development over immediate shareholder value generation, a common strategy for growth-stage biotechs.

バリュエーション評価

Valuation multiples for Legend Biotech present a complex picture, with a trailing P/E ratio marked as N/A due to negative earnings and a forward P/E of 15.83, which implies market expectations for future earnings normalization as the company transitions toward profitability. The price-to-book ratio stands at 3.36, indicating that the market values the company at a significant premium over its tangible book value, likely reflecting the high intangible value of its intellectual property and clinical pipeline. Alternative valuation metrics such as the price-to-sales ratio of 3.27 and an EV/EBITDA of -48.76 suggest that investors are pricing the stock based on revenue generation potential rather than current earnings power or cash flow generation. In terms of trading range, the stock has a 52-week high of $45.30 and a 52-week low of $16.24, with the current price situated somewhere within this volatility band subject to market sentiment regarding its clinical milestones. The beta value is recorded at 0.08, which indicates that the stock price exhibits minimal sensitivity to broader market movements, behaving differently from the high volatility typically associated with small-cap biotechnology equities.

Growth & Income

Revenue growth year-over-year is a robust 64.2%, whereas earnings growth is listed as N/A due to the company's current unprofitable status, implying that top-line expansion is outpacing the realization of net earnings. As a non-dividend payer, Legend Biotech does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all earnings to reinvest into its research and development programs rather than providing income to shareholders. This reinvestment strategy is characteristic of biotechnology firms that sacrifice current income distribution to accelerate clinical progression and commercial launch of novel cell therapies. The overall growth and income profile is defined by rapid revenue expansion funded by internal cash reserves and external capital, with no current focus on generating shareholder yield through dividends or buybacks.